For prostate cancer, a pilot study including 23 patients with hormone-refractory prostate cancer receiving candesartan dating from 2005 reported a decrease in serum levels of prostate-specific antigen in 8 patients and stable or improved performance status (92). This evidence concerns the gene KLK3 and prostate carcinoma.